The state of Colorado currently has 14 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including Denver, Aurora, Colorado Springs and Englewood.
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Recruiting
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most. To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB. Clinicians use the C... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
03/26/2024
Locations: Rocky Mountain Movement Disorders Center, PC, Englewood, Colorado
Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
Recruiting
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
03/20/2024
Locations: Denver Neurological Research, Denver, Colorado +1 locations
Conditions: Alzheimer Disease
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 65 years and 80 years
Trial Updated:
03/13/2024
Locations: Care Access - Aurora, Aurora, Colorado +2 locations
Conditions: Alzheimer Disease
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
Recruiting
This study seeks to improve clinical outcomes for an important, growing, and vulnerable population-nursing home residents with Alzheimer's disease or related dementias-by testing an evidence-based intervention to improve these residents' sleep. It will also examine the implementation and sustainment of this intervention.
Gender:
All
Ages:
50 years and above
Trial Updated:
03/11/2024
Locations: Vivage/Beecan Corporation, Lakewood, Colorado
Conditions: Alzheimer Disease, Dementia, Sleep Disorder, Sleep Disturbance
Trial-Ready Cohort-Down Syndrome (TRC-DS)
Recruiting
The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 250 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-DS) study. Participants enrolled in the TRC-DS will undergo longitudinal cognitive and clinical assessment, genetic and biomarker testing, as well as imaging and biospecimen collection. Using these outc... Read More
Gender:
All
Ages:
Between 25 years and 55 years
Trial Updated:
03/06/2024
Locations: Linda Crnic Institute for Down Syndrome, University of Colorado, Aurora, Colorado
Conditions: Down Syndrome, Alzheimer Disease, Dementia
A Diagnostic Test for Dementia With Lewy Bodies
Recruiting
The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
03/06/2024
Locations: CenExel RMCR, Englewood, Colorado
Conditions: MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Recruiting
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
02/29/2024
Locations: Mountain Neurological Research Center, Basalt, Colorado +2 locations
Conditions: Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Recruiting
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason and safety and tolerability in subjects wit... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
02/29/2024
Locations: Clinical Trial Site, Colorado Springs, Colorado
Conditions: Psychosis Associated With Alzheimer's Disease
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
Recruiting
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
02/15/2024
Locations: Sage Investigational Site, Englewood, Colorado
Conditions: Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
Recruiting
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 530 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State E... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
01/20/2024
Locations: Mile High Research Center, Denver, Colorado
Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease
Recruiting
A medicine that is FDA-approved for bone marrow stimulation (called sargramostim) will be tested for its safety and efficacy in individuals with mild-to-moderate Alzheimer's disease over a six month treatment period.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
01/04/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Alzheimer Disease
"Safety in Dementia": An Online Caregiver Intervention
Recruiting
In an online randomized trial of Safety in Dementia with national recruitment and longitudinal follow-up, we will recruit informal caregivers of community-dwelling adults with dementia who have firearm access.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: University of Colorado Anschutz, Aurora, Colorado
Conditions: Caregivers, Decision Making, Alzheimer Disease, Social Media, Safety, Suicide